BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17727318)

  • 1. High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction.
    Elmas E; Lang S; Dempfle CE; Kälsch T; Hannak D; Sueselbeck T; Wolpert C; Borggrefe M; Brueckmann M
    Clin Chem Lab Med; 2007; 45(10):1360-5. PubMed ID: 17727318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced proinflammatory response of mononuclear cells to in vitro LPS-challenge in patients with ventricular fibrillation in the setting of acute myocardial infarction.
    Elmas E; Hölzer L; Lang S; Popp T; Kälsch T; Wolpert C; Brueckmann M; Borggrefe M
    Cytokine; 2008 Aug; 43(2):138-42. PubMed ID: 18571935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imbalance between tissue inhibitor of metalloproteinase 1 and matrix metalloproteinase 9 after cardiopulmonary resuscitation.
    Li JS; Zhong JQ; Liu HZ; Zeng QX; Meng XL; Liu DL; Su GY; Zhang Y
    Am J Emerg Med; 2012 Sep; 30(7):1202-9. PubMed ID: 22030200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
    Wang W; Zhang HT; Yang XL
    J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction.
    Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Clark LT; Pinsky DJ; Marmur JD
    Am Heart J; 2006 May; 151(5):1101.e1-8. PubMed ID: 16644343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
    Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
    Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
    Webb CS; Bonnema DD; Ahmed SH; Leonardi AH; McClure CD; Clark LL; Stroud RE; Corn WC; Finklea L; Zile MR; Spinale FG
    Circulation; 2006 Sep; 114(10):1020-7. PubMed ID: 16923753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of matrix metalloproteinase-1, matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1, and interleukin-6 with epicardial and myocardial perfusion.
    Tanindi A; Sahinarslan A; Elbeg S; Cemri M
    Coron Artery Dis; 2011 Jun; 22(4):253-8. PubMed ID: 21317638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction.
    Kelly D; Squire IB; Khan SQ; Dhillon O; Narayan H; Ng KH; Quinn P; Davies JE; Ng LL
    Am J Cardiol; 2010 Aug; 106(4):477-82. PubMed ID: 20691304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction.
    Tan J; Hua Q; Gao J; Fan ZX
    Clin Cardiol; 2008 Sep; 31(9):413-8. PubMed ID: 18781600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
    Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty.
    Kuliczkowski W; Urbaniak J; Hallén J; Woźniak M; Poloński L; Mysiak A; Atar D; Zembala M; Serebruany V
    Kardiol Pol; 2013; 71(5):453-63. PubMed ID: 23788085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
    Furenes EB; Arnesen H; Solheim S; Grøgaard HK; Hoffmann P; Seljeflot I
    Thromb Res; 2009 Nov; 124(5):560-4. PubMed ID: 19410278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolytic and cytokine balance abnormalities in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass.
    Paśnik J; Moll J; Cywińska-Bernas A; Moll J; Sysa A; Zeman K
    Kardiol Pol; 2007 Oct; 65(10):1208-14; discussion 1215. PubMed ID: 17979049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction.
    Halapas A; Zacharoulis A; Theocharis S; Karavidas A; Korres D; Papadopoulos K; Katopodis H; Stavropoulou A; Lembessis P; Xiromeritis C; Zacharoulis A; Koutsilieris M
    Clin Chem Lab Med; 2008; 46(4):510-6. PubMed ID: 18298349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome.
    Cheng M; Hashmi S; Mao X; Zeng QT
    Can J Cardiol; 2008 May; 24(5):385-90. PubMed ID: 18464944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFFECT OF RELATIVE GENE EXPRESSION ON PLAQUE VULNERABILITY IN PATIENTS WITH STABLE ANGINA AND PATIENTS WITH ACUTE CORONARY SYNDROME.
    Chen N; Zhang JY; Yang SZ; Li YD
    J Biol Regul Homeost Agents; 2015; 29(2):437-41. PubMed ID: 26122234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects.
    Holven KB; Halvorsen B; Bjerkeli V; Damås JK; Retterstøl K; Mørkrid L; Ose L; Aukrust P; Nenseter MS
    Stroke; 2006 Jul; 37(7):1731-6. PubMed ID: 16728689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.